Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Saw Bezos with that 82 year old woman he wants to take into space end of month (made me cringe), well, Branson will beat that and be going full flight July 11th announced last night !!!
Trendtraderz: Over the last two years the SEC has successfully litigated to revoke over 500 Securities that have refused to file Financials. AMZO hasn't filed any Financials in 4 1/2 years.
The SEC moves very fast once they file an Admin Proceeding to revoke a registration.
I will provide evidence of the 500+ revocations if you request it.
As simple as I can put it, AMZO files Financials immediately, toute-de-suite, right the heck NOW or this stock will likely be revoked within a few weeks.
AMZO will open on the Grey Sheets after the Suspension expires. Although it would be irresponsible for me to suggest that you sell out I know that I would sell as fast as I could if I owned any AMZO stock.
Best o'luck, Trendtraderz....sincerely!!!
Excerpt from the ADMIN Proceeding: Amazon Biotech, Inc. (“AMZO”) (CIK No. 1088781) is an expired Utah corporation located in West Palm Beach, Florida with a class of securities registered with the Commission pursuant to Exchange Act Section 12(g). AMZO is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 10-QSB for the period ended October 31, 2007
More Excerpts:
DELINQUENT PERIODIC FILINGS
7. As discussed in more detail above, all of the Respondents are delinquent in their periodic filings with the Commission, have repeatedly failed to meet their obligations to file timely periodic reports, and failed to heed delinquency letters sent to them by the Division of Corporation Finance requesting compliance with their periodic filing obligations or, through their failure to maintain a valid address on file with the Commission as required by Commission rules, did not receive such letters.
B. Whether it is necessary and appropriate for the protection of investors to suspend for a period not exceeding twelve months, or revoke the registration of each class of securities registered pursuant to Section 12 of the Exchange Act of the Respondents identified in Section II hereof, and any successor under Exchange Act Rules 12b-2 or 12g-3, and any new corporate names of any Respondents.
Renee could I bother you to please explain to me what exactly the company needs to do to restore itself to the OTC. Does the company need to make a plan to file the delinquent financials etc...? I do not know any of the process that happens with one of these suspended securities. So if you could please be detailed that would be awesome. p.s. nobody on ihub is better than you at explaining these types of things. And I really appreciate it!
AMZO SEC Suspension:
http://www.sec.gov/litigation/suspensions/2012/34-66545.pdf
SEC Admin Proceeding:
http://www.sec.gov/litigation/admin/2012/34-66546.pdf
List of patents held by the CEO Chaim Lieberman.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=%2220100221806%22.PGNR.
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7160561.PN.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=%2220050053564%22.PGNR.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=%2220050053564%22.PGNR.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=%2220040265335%22.PGNR.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=%2220040258712%22.PGNR.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=%2220040234546%22.PGNR.
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=5707631.PN.
A nice little list of patents. Now that the litigation has been dismissed and the company is back on track, things will be moving forward. I know they got a couple of LOI's lined up as well as an acquisition.
Things should be rocking here forthcoming. The litigation that was not allowing the company to "move forward" was dismissed in District Court in Utah.
http://ia600706.us.archive.org/18/items/gov.uscourts.utd.76292/gov.uscourts.utd.76292.23.0.pdf
If you email-
cj@amazonbiotech.com
dr.silver@amazonbiotech.com
You will get all the answers you will need. With this float and how it moves up to .05 plus I am in! Enjoy.
Bradkus, Volume seems to be picking up. You stated, "Watch!" Do you have a reason?
Downside risk is taken out of this stock. Financing is taking time, but will come. Enough cash on hand to last until already approved trials. Great opportunity to get in at the bottom.
This should see some action once the financing is annouced, which will be any day. IMO.
AMZB picking up volume for some reason. Something might be brewing IMO.
That charts looks good buddy.
I think this is one of those summer stocks that people will always talk about. If that drug gets to the market, then we could have an interesting summer. I believe those negotiations will come through IMO.
Called it a high breakout potential a few days ago; it broke out...
...I am always glad to see that TA works.
GLTY
looking good from here onwards.
Which one on the list are they negotiating with?
3M
Abbott Laboratories
Bristol-Myers Squibb
FermaVir Pharmaceuticals
Gilead Sciences
Hemispherx Biopharma
MedImmune Inc.
Merck & Co.
Novartis Pharmaceuticals
Novelos Therapeutics
Panacos Pharmaceuticals
Pfizer Inc.
Pharmasset
Schering-Plough Corporation
Re: AMZB - TA in annotated chart
One of my most bullish-indicator screened this week-end:
GLTYA
Regulatory Environment for HIV/AIDS in the US
Product Launches
Strategic Corporate Developments
Focus on Key Players
3M
Abbott Laboratories
Amazon Biotech##
Bristol-Myers Squibb
FermaVir Pharmaceuticals
Gilead Sciences
Hemispherx Biopharma
MedImmune Inc.
Merck & Co.
Novartis Pharmaceuticals
Novelos Therapeutics
Panacos Pharmaceuticals
Pfizer Inc.
Pharmasset
Schering-Plough Corporation
http://pharmalicensing.com/intelligence/reportsearching.php?action=toc&productID=1389772
Amazon Biotech Inc. in Early Negotiations With Major Pharmaceutical Companies
Friday , March 30, 2007 16:05ET
NEW YORK, NY -- (MARKET WIRE) -- 03/30/07 -- Amazon Biotech, Inc. (OTC BB: AMZB) (FRANKFURT: B2D) announced that it has secured the services of Mr. Stanley Fass to negotiate a joint venture agreement between Amazon Biotech and major pharmaceutical companies.
Amazon Biotech has entered in negotiations with major pharmaceutical companies for funding of Future studies and marketing of the company\'s anti-HIV drug, AMZ0026 which has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Mr. Fass had previously been with Intec Pharma Ltd. as vice president business development where he successfully negotiated a joint venture with Glaxo SmithKline (GSK). He also served as President of Perio Products, Ltd. for 12 years where he successfully negotiated joint venture agreements with Astra Pharmaceuticals, Procter & Gamble, Carter-Wallace, Colgate, Novartis, AL Pharma, IofI in Japan, amongst others.
Dr. Mechael Kanovsky, CEO of Amazon Biotech, said, "The negotiations are in early stages and there is no assurance that any of these negotiations will lead to a joint venture deal. However, we are pleased that a number of large pharmaceutical companies have shown preliminary interest in our phytopharmaceutical drug product."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company\'s first such drug, which is to be used for the treatment of HIV/AIDS. The company plans, upon funding, to initiate Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. All negotiations that are currently going on with major pharmaceutical companies are in the early stages and may not lead to any agreements or contracts. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech\'s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
--------------------------------------------------------------------------------Contact:
LC Group
Rick Lutz
(404) 261-1196
Source: Amazon Biotech, Inc.
I PREDICT this stock to do very well in the comming days, just look at the news it has potential to run a few days. I got in ONCM at 0.0011 and sold at 0.0018 in a few days, THIS IS MY NEXT PICK BRUHAHAHAHA. This board seems extremely dead lmao but sometimes all it takes is one to believe. GLUCK ALL
AMZB is a popularily shorted stock. With no product, one could understand why.
AMZB has had ZERO income in the past 4 years only expense! Is there even a AMZ0026 product?? I think the so called "expenses" are payments to company insiders.
I would not buy this stock EVER!
Balance sheet:
http://finance.yahoo.com/q/is?s=AMZB.OB&annual
The market maker, VFIN is currently sitting on the ask. With the heavy promoting being done I would be very cautious on buying shares of this company. VFinance is a known diluter. To any inexperienced investors: companies dilute shares to raise capital, sometimes fueled by fraudulant claims, hype building, and heavy promotion.
More information on dilution:
http://www.answers.com/topic/stock-dilution
Article on *Stock SCAM* ran by VFinance (VFIN):
http://www.phillyimc.org/en/2006/12/34919.shtml
You can Google "VFIN scam fraud" for additional information.
Dipping today...nice time to reenter probably
Not looking at either of these companies debt structure Appi and this one could make good partners.
got rid of my shares and bought axtg at 1.70. Very wise move if you ask me. I lost 30% on amzb and have gained around 50% on axtg in a couple of days
I would just stick this one on the back burner for now. AMZB will need to issue alot of new stock just to cover operations in the coming quarters.
NVM. very slow today.
It seems like .14- .16 will be the average range for a while till anything new happens..
yes did see the huge EOD run yesterday.
Today,Went upto .16 then sells!! sigh..
I do believe in this company though, they are definitely doing good for the mankind.
I picked up some yesteday as well...looks to be gappin up this morning ...did anyone notice the huge buys EOD ?
Thanks, my marketing guys are currently trying to arrange a meeting with them to make their site better and much more informative for investors (logins etc.)
Link to Amazon's Website
http://www.amazonbiotech.com/index.htm
bought some this morning after hearing about this company for the first time. Seems like they have some good things going for them.
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
45
|
Created
|
09/06/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |